within Pharmacolibrary.Drugs.D_Dermatologicals.D10A_AntiAcnePreparationsForTopicalUse.D10AA02_Methylprednisolone;

model Methylprednisolone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 4.083333333333333e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.038799999999999994,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0259,
    k12 = 5.333333333333333e-06,
    k21 = 5.333333333333333e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Methylprednisolone</td></tr><tr><td>ATC code:</td><td>D10AA02</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>38.8</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14.7</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Methylprednisolone is a synthetic glucocorticoid used primarily as an anti-inflammatory and immunosuppressant. It is indicated for a broad range of conditions, including allergies, asthma, autoimmune diseases, and certain types of arthritis. It is approved and widely used in clinical medicine.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after a single intravenous bolus. Both male and female subjects included, age range 18-45, with normal renal and hepatic function.</p><h4>References</h4><ol><li><p>Barth, J, et al., &amp; Möllenhoff, G (2004). Population pharmacokinetics of methylprednisolone in accident victims with spinal cord injury. <i>International journal of clinical pharmacology and therapeutics</i> 42(9) 504–511. DOI:<a href=\"https://doi.org/10.5414/cpp42504\">10.5414/cpp42504</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15487809/\">https://pubmed.ncbi.nlm.nih.gov/15487809</a></p></li><li><p>Hornik, CP, et al., &amp; Cohen-Wolkowiez, M (2019). Population Pharmacokinetic/Pharmacodynamic Modeling of Methylprednisolone in Neonates Undergoing Cardiopulmonary Bypass. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 8(12) 913–922. DOI:<a href=\"https://doi.org/10.1002/psp4.12470\">10.1002/psp4.12470</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31646767/\">https://pubmed.ncbi.nlm.nih.gov/31646767</a></p></li><li><p>Fokkink, WJR, et al., &amp; Jacobs, BC (2022). Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome. <i>Clinical pharmacokinetics</i> 61(9) 1285–1296. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01136-z\">10.1007/s40262-022-01136-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35781631/\">https://pubmed.ncbi.nlm.nih.gov/35781631</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.D.D10AA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Methylprednisolone;
